In today’s fast-changing regulatory environment, Real World Evidence (RWE) surrounding Safety, Comparative effectiveness and Outcomes have become a critical part of the Medical affairs and pre-commercialization strategy. As a result, we have noticed RWE being incorporated into shaping the clinical development strategy. However, when entering new markets or regions, it is important to recognize key challenges to generate fit-for-purpose evidence and learn how to overcome these barriers.

Through this webinar, we would like to share our learnings and key considerations when planning and executing an integrated evidence generation approach. The session tailored for the emerging biopharma will cover the following key objectives:

• Benefits and key considerations of incorporating an evidence strategy earlier in the product lifecycle
• Understanding various use cases for RWE ranging from regulatory submissions, HTA, pricing and reimbursement
• Strengthening product value proposition in US, EU and APAC
• Coverage on US, China, and APAC Real-world Data landscape
• Understanding alternative and faster access to RWE data strategies and key considerations with respect to timeline, cost, and operational execution to enable faster, more efficient evidence generation for real-world studies

Click here to register for this webinar.